Growth Metrics

Supernus Pharmaceuticals (SUPN) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$45.1 million.

  • Supernus Pharmaceuticals' Income towards Parent Company fell 21719.61% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 13194.75%. This contributed to the annual value of $73.9 million for FY2024, which is 551284.19% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Income towards Parent Company stood at -$45.1 million for Q3 2025, which was down 21719.61% from $22.5 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Income towards Parent Company ranged from a high of $38.5 million in Q3 2024 and a low of -$45.1 million during Q3 2025
  • Over the past 5 years, Supernus Pharmaceuticals' median Income towards Parent Company value was $7.8 million (recorded in 2022), while the average stood at $8.1 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 250652.96% in 2024, then plummeted by 964112.9% in 2025.
  • Supernus Pharmaceuticals' Income towards Parent Company (Quarter) stood at $2.4 million in 2021, then skyrocketed by 943.45% to $25.5 million in 2022, then plummeted by 95.39% to $1.2 million in 2023, then skyrocketed by 1208.68% to $15.4 million in 2024, then tumbled by 393.41% to -$45.1 million in 2025.
  • Its Income towards Parent Company stands at -$45.1 million for Q3 2025, versus $22.5 million for Q2 2025 and -$11.8 million for Q1 2025.